Business
Arius to present at Rodman & Renshaw Healthcare Conference
TORONTO, Nov. 6 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and ...
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, Nov. 6 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced that Dr. David S. Young, President and Chief Executive Officer\nof the Company, will present at the Acumen BioFin Rodman & Renshaw 9th Annual\nHealthcare Conference. Dr. Young will provide an update on the Company's three\nlead anti-cancer antibody programs targeting CD44, Trop-2 and CD59.\n\n\nThe conference is being held at the New York Palace Hotel in New York\nCity and ARIUS' presentation is scheduled for Wednesday, November 7th at\n2:20pm EST in the Holmes II Room.\n\n\nAbout ARIUS\n\n\nARIUS is a biotechnology company discovering and developing the next wave\nof antibody therapeutics. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies and selects\nantibodies based on their functional ability to affect disease. This antibody\ngeneration engine has enabled ARIUS to assemble a portfolio of more than\n500 antibody candidates. In addition to the antibodies it is developing\nin-house, ARIUS has ongoing partnerships with key biotechnology and drug\ndevelopment companies. ARIUS is listed on the TSX under the symbol "ARI". For\nfurther information, visit www.ariusresearch.com\n\n\nForward-Looking Statements\n\n\nCertain statements in this news release constitute "forward-looking\nstatements" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown risks, uncertainties and other\nfactors that may cause our actual results to be materially different from any\nfuture results, performance or achievements expressed or implied by such\nstatements. Forward-looking statements in this release include, but are not\nlimited to, ARIUS successfully advancing its new product programs as well as\nlicensing opportunities. These statements are only predictions and actual\nevents or results may differ materially. Factors that could cause such actual\nevents or results expressed or implied by such forward-looking statements to\ndiffer materially from any future results expressed or implied by such\nstatements include, but are not limited to: early stage of development;\ntechnology and product development; dependence on and management of curre...